×




QuintilesIMS: Biosimilar Marketing in England Net Present Value (NPV) / MBA Resources

Introduction to Net Present Value (NPV) - What is Net Present Value (NPV) ? How it impacts financial decisions regarding project management?

NPV solution for QuintilesIMS: Biosimilar Marketing in England case study


At Oak Spring University, we provide corporate level professional Net Present Value (NPV) case study solution. QuintilesIMS: Biosimilar Marketing in England case study is a Harvard Business School (HBR) case study written by John A. Quelch, Emily C. Boudreau. The QuintilesIMS: Biosimilar Marketing in England (referred as “Quintilesims Biosimilar” from here on) case study provides evaluation & decision scenario in field of Sales & Marketing. It also touches upon business topics such as - Value proposition, Marketing.

The net present value (NPV) of an investment proposal is the present value of the proposal’s net cash flows less the proposal’s initial cash outflow. If a project’s NPV is greater than or equal to zero, the project should be accepted.

NPV = Present Value of Future Cash Flows LESS Project’s Initial Investment






Case Description of QuintilesIMS: Biosimilar Marketing in England Case Study


QuintilesIMS was a leading healthcare consulting firm best known for its data and information offerings, as well as its market research and management consulting services for life science companies. By 2015, the company was expanding beyond the biopharmaceutical industry, offering analytical services to healthcare systems, like the National Health Service (NHS) in the United Kingdom (UK). In June, 2015, QuintilesIMS published a study highlighting inconsistencies in the care of RA patients in England. In particular, the company considered the current use of biologic medications to treat RA in England, as well how the introduction of biosimilar medications might affect costs to the NHS and medication access for patients. Students must use epidemiology, cost, and market share information given in the case to estimate potential cost savings one year after the introduction of biosimilars. The case also explores qualitative questions around the appropriate communication with patients and the role of QuintilesIMS.


Case Authors : John A. Quelch, Emily C. Boudreau

Topic : Sales & Marketing

Related Areas : Marketing




Calculating Net Present Value (NPV) at 6% for QuintilesIMS: Biosimilar Marketing in England Case Study


Years              Cash Flow     Net Cash Flow     Cumulative    
Cash Flow
Discount Rate
@ 6 %
Discounted
Cash Flows
Year 0 (10009043) -10009043 - -
Year 1 3459586 -6549457 3459586 0.9434 3263760
Year 2 3981687 -2567770 7441273 0.89 3543687
Year 3 3974325 1406555 11415598 0.8396 3336920
Year 4 3226462 4633017 14642060 0.7921 2555660
TOTAL 14642060 12700028




The Net Present Value at 6% discount rate is 2690985

In isolation the NPV number doesn't mean much but put in right context then it is one of the best method to evaluate project returns. In this article we will cover -

Different methods of capital budgeting


What is NPV & Formula of NPV,
How it is calculated,
How to use NPV number for project evaluation, and
Scenario Planning given risks and management priorities.




Capital Budgeting Approaches

Methods of Capital Budgeting


There are four types of capital budgeting techniques that are widely used in the corporate world –

1. Payback Period
2. Net Present Value
3. Profitability Index
4. Internal Rate of Return

Apart from the Payback period method which is an additive method, rest of the methods are based on Discounted Cash Flow technique. Even though cash flow can be calculated based on the nature of the project, for the simplicity of the article we are assuming that all the expected cash flows are realized at the end of the year.

Discounted Cash Flow approaches provide a more objective basis for evaluating and selecting investment projects. They take into consideration both –

1. Timing of the expected cash flows – stockholders of Quintilesims Biosimilar have higher preference for cash returns over 4-5 years rather than 10-15 years given the nature of the volatility in the industry.
2. Magnitude of both incoming and outgoing cash flows – Projects can be capital intensive, time intensive, or both. Quintilesims Biosimilar shareholders have preference for diversified projects investment rather than prospective high income from a single capital intensive project.






Formula and Steps to Calculate Net Present Value (NPV) of QuintilesIMS: Biosimilar Marketing in England

NPV = Net Cash In Flowt1 / (1+r)t1 + Net Cash In Flowt2 / (1+r)t2 + … Net Cash In Flowtn / (1+r)tn
Less Net Cash Out Flowt0 / (1+r)t0

Where t = time period, in this case year 1, year 2 and so on.
r = discount rate or return that could be earned using other safe proposition such as fixed deposit or treasury bond rate. Net Cash In Flow – What the firm will get each year.
Net Cash Out Flow – What the firm needs to invest initially in the project.

Step 1 – Understand the nature of the project and calculate cash flow for each year.
Step 2 – Discount those cash flow based on the discount rate.
Step 3 – Add all the discounted cash flow.
Step 4 – Selection of the project

Why Sales & Marketing Managers need to know Financial Tools such as Net Present Value (NPV)?

In our daily workplace we often come across people and colleagues who are just focused on their core competency and targets they have to deliver. For example marketing managers at Quintilesims Biosimilar often design programs whose objective is to drive brand awareness and customer reach. But how that 30 point increase in brand awareness or 10 point increase in customer touch points will result into shareholders’ value is not specified.

To overcome such scenarios managers at Quintilesims Biosimilar needs to not only know the financial aspect of project management but also needs to have tools to integrate them into part of the project development and monitoring plan.

Calculating Net Present Value (NPV) at 15%

After working through various assumptions we reached a conclusion that risk is far higher than 6%. In a reasonably stable industry with weak competition - 15% discount rate can be a good benchmark.



Years              Cash Flow     Net Cash Flow     Cumulative    
Cash Flow
Discount Rate
@ 15 %
Discounted
Cash Flows
Year 0 (10009043) -10009043 - -
Year 1 3459586 -6549457 3459586 0.8696 3008336
Year 2 3981687 -2567770 7441273 0.7561 3010727
Year 3 3974325 1406555 11415598 0.6575 2613183
Year 4 3226462 4633017 14642060 0.5718 1844740
TOTAL 10476986


The Net NPV after 4 years is 467943

(10476986 - 10009043 )








Calculating Net Present Value (NPV) at 20%


If the risk component is high in the industry then we should go for a higher hurdle rate / discount rate of 20%.

Years              Cash Flow     Net Cash Flow     Cumulative    
Cash Flow
Discount Rate
@ 20 %
Discounted
Cash Flows
Year 0 (10009043) -10009043 - -
Year 1 3459586 -6549457 3459586 0.8333 2882988
Year 2 3981687 -2567770 7441273 0.6944 2765060
Year 3 3974325 1406555 11415598 0.5787 2299957
Year 4 3226462 4633017 14642060 0.4823 1555971
TOTAL 9503977


The Net NPV after 4 years is -505066

At 20% discount rate the NPV is negative (9503977 - 10009043 ) so ideally we can't select the project if macro and micro factors don't allow financial managers of Quintilesims Biosimilar to discount cash flow at lower discount rates such as 15%.





Acceptance Criteria of a Project based on NPV

Simplest Approach – If the investment project of Quintilesims Biosimilar has a NPV value higher than Zero then finance managers at Quintilesims Biosimilar can ACCEPT the project, otherwise they can reject the project. This means that project will deliver higher returns over the period of time than any alternate investment strategy.

In theory if the required rate of return or discount rate is chosen correctly by finance managers at Quintilesims Biosimilar, then the stock price of the Quintilesims Biosimilar should change by same amount of the NPV. In real world we know that share price also reflects various other factors that can be related to both macro and micro environment.

In the same vein – accepting the project with zero NPV should result in stagnant share price. Finance managers use discount rates as a measure of risk components in the project execution process.

Sensitivity Analysis

Project selection is often a far more complex decision than just choosing it based on the NPV number. Finance managers at Quintilesims Biosimilar should conduct a sensitivity analysis to better understand not only the inherent risk of the projects but also how those risks can be either factored in or mitigated during the project execution. Sensitivity analysis helps in –

What are the uncertainties surrounding the project Initial Cash Outlay (ICO’s). ICO’s often have several different components such as land, machinery, building, and other equipment.

What can impact the cash flow of the project.

Understanding of risks involved in the project.

What will be a multi year spillover effect of various taxation regulations.

What are the key aspects of the projects that need to be monitored, refined, and retuned for continuous delivery of projected cash flows.

Some of the assumptions while using the Discounted Cash Flow Methods –

Projects are assumed to be Mutually Exclusive – This is seldom the came in modern day giant organizations where projects are often inter-related and rejecting a project solely based on NPV can result in sunk cost from a related project.

Independent projects have independent cash flows – As explained in the marketing project – though the project may look independent but in reality it is not as the brand awareness project can be closely associated with the spending on sales promotions and product specific advertising.






Negotiation Strategy of QuintilesIMS: Biosimilar Marketing in England

References & Further Readings

John A. Quelch, Emily C. Boudreau (2018), "QuintilesIMS: Biosimilar Marketing in England Harvard Business Review Case Study. Published by HBR Publications.


Dutaland SWOT Analysis / TOWS Matrix

Consumer/Non-Cyclical , Crops


Starburst Holdings Ltd SWOT Analysis / TOWS Matrix

Capital Goods , Construction Services


Panthera Resources SWOT Analysis / TOWS Matrix

Basic Materials , Gold & Silver


Taiho Kogyo Co Ltd SWOT Analysis / TOWS Matrix

Consumer Cyclical , Auto & Truck Parts


Shinvest Holding SWOT Analysis / TOWS Matrix

Basic Materials , Misc. Fabricated Products


Nitto Boseki SWOT Analysis / TOWS Matrix

Consumer/Non-Cyclical , Personal & Household Prods.


Analytica Ltd SWOT Analysis / TOWS Matrix

Healthcare , Medical Equipment & Supplies


Soo Kee SWOT Analysis / TOWS Matrix

Basic Materials , Misc. Fabricated Products


Tara Jewels Ltd SWOT Analysis / TOWS Matrix

Consumer Cyclical , Jewelry & Silverware